Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: A bayesian meta-analysis

Scott M. Berry; Kristine R. Broglio; Donald A. Berry

doi:10.3109/07357907.2011.568563

Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: A bayesian meta-analysis

Scott M. Berry, Kristine R. Broglio, Donald A. Berry

Biostatistics

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

IL-2 has been investigated as maintenance therapy for patients with AML in five randomized trials. None has shown a statistically significant benefit. A randomized trial of HDC + IL-2 showed a statistically significant benefit for leukemia-free survival (LFS) in comparison with standard of care. Because HDC + IL-2 has not been randomized against IL-2 alone, the question remains as to whether and to what extent HDC + IL-2 is an improvement compared to IL-2 alone. This is a literature-based meta-analysis. We employ two versions of a Bayesian hierarchical model to compare HDC + IL-2 versus IL-2 alone on the basis of LFS in patients in remission from AML.

Original language	English (US)
Pages (from-to)	293-299
Number of pages	7
Journal	Cancer Investigation
Volume	29
Issue number	4
DOIs	https://doi.org/10.3109/07357907.2011.568563
State	Published - May 2011

Keywords

Biostatistics
Clinical trials
Leukemias

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3109/07357907.2011.568563

Cite this

@article{85005cb30bf644feb2a98172beaf302b,

title = "Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: A bayesian meta-analysis",

abstract = "IL-2 has been investigated as maintenance therapy for patients with AML in five randomized trials. None has shown a statistically significant benefit. A randomized trial of HDC + IL-2 showed a statistically significant benefit for leukemia-free survival (LFS) in comparison with standard of care. Because HDC + IL-2 has not been randomized against IL-2 alone, the question remains as to whether and to what extent HDC + IL-2 is an improvement compared to IL-2 alone. This is a literature-based meta-analysis. We employ two versions of a Bayesian hierarchical model to compare HDC + IL-2 versus IL-2 alone on the basis of LFS in patients in remission from AML.",

keywords = "Biostatistics, Clinical trials, Leukemias",

author = "Berry, {Scott M.} and Broglio, {Kristine R.} and Berry, {Donald A.}",

year = "2011",

month = may,

doi = "10.3109/07357907.2011.568563",

language = "English (US)",

volume = "29",

pages = "293--299",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia

T2 - A bayesian meta-analysis

AU - Berry, Scott M.

AU - Broglio, Kristine R.

AU - Berry, Donald A.

PY - 2011/5

Y1 - 2011/5

N2 - IL-2 has been investigated as maintenance therapy for patients with AML in five randomized trials. None has shown a statistically significant benefit. A randomized trial of HDC + IL-2 showed a statistically significant benefit for leukemia-free survival (LFS) in comparison with standard of care. Because HDC + IL-2 has not been randomized against IL-2 alone, the question remains as to whether and to what extent HDC + IL-2 is an improvement compared to IL-2 alone. This is a literature-based meta-analysis. We employ two versions of a Bayesian hierarchical model to compare HDC + IL-2 versus IL-2 alone on the basis of LFS in patients in remission from AML.

AB - IL-2 has been investigated as maintenance therapy for patients with AML in five randomized trials. None has shown a statistically significant benefit. A randomized trial of HDC + IL-2 showed a statistically significant benefit for leukemia-free survival (LFS) in comparison with standard of care. Because HDC + IL-2 has not been randomized against IL-2 alone, the question remains as to whether and to what extent HDC + IL-2 is an improvement compared to IL-2 alone. This is a literature-based meta-analysis. We employ two versions of a Bayesian hierarchical model to compare HDC + IL-2 versus IL-2 alone on the basis of LFS in patients in remission from AML.

KW - Biostatistics

KW - Clinical trials

KW - Leukemias

UR - http://www.scopus.com/inward/record.url?scp=79953795365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953795365&partnerID=8YFLogxK

U2 - 10.3109/07357907.2011.568563

DO - 10.3109/07357907.2011.568563

M3 - Article

C2 - 21469978

AN - SCOPUS:79953795365

SN - 0735-7907

VL - 29

SP - 293

EP - 299

JO - Cancer Investigation

JF - Cancer Investigation

IS - 4

ER -

Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: A bayesian meta-analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this